Specific Biologics Inc. recently announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sciences companies.

Gene editing holds the potential to cure a wide range of genetic diseases by altering DNA in the genome inside cells – but today's gene editors have limitations. To better realize the significant opportunity of this therapeutic approach, and allow for its application to new therapeutic areas, Specific Biologics has developed the unique next-generation Dualase™ gene editing platform which can more accurately alter DNA sequences by cutting DNA in two spots as a single molecule. Specific has demonstrated the benefit of this two-site mechanism in proof-of-concept studies in disease-relevant models.

Specific Biologics is an OBIO Member company and a presenting company at the 2022 OBIO Investment Summit.